» Articles » PMID: 35117796

Clinical Value and Feasibility of ISET in Detecting Circulating Tumor Cells in Early Breast Cancer

Overview
Specialty Oncology
Date 2022 Feb 4
PMID 35117796
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with operable breast cancer have a better prognosis for recovery. However, once distant organ metastasis occurs, the chance of a long-term survival or a cure is limited. The collection and counting of circulating tumor cells (CTCs) by reliable detection techniques are of increasing importance in the diagnosis of early metastasis and prognosis of disease progression. Isolation by size of epithelial tumor cells (ISET) has the advantage of simplicity of operation and high homogeneity. It is practical for large-scale clinical detection showing cell abundance. The value of ISET in the detection of circulating breast cancers in the blood has not been determined. The purpose of this study is to explore the feasibility of applying ISET to detect CTCs by determining the detection rate of ISET in operable breast cancer and by evaluating the correlation between detection rate, cell count and clinical factors such as molecular typing and pathological staging.

Methods: The experiment included 193 breast cancer patients who were diagnosed by core needle biopsy before the operation. 10 mL of venous blood was collected from the patients preoperatively, and CTCs in their blood samples were counted and analyzed by ISET.

Results: Patients were divided into groups according to pathology and immunohistochemistry. The overall detection rate of CTCs by ISET was 41.24%. The detection rate, the number of overall CTCs and the average number of CTCs in each group were analyzed individually. No significant differences were observed between the different groups.

Conclusions: Although ISET has a relatively good detection rate for circulating breast cancer cells, it fails to provide more information on pathological staging, molecular classification and so forth.

Citing Articles

Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?.

Fridrichova I, Kalinkova L, Ciernikova S Int J Mol Sci. 2022; 23(20).

PMID: 36292996 PMC: 9603393. DOI: 10.3390/ijms232012141.


Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases.

Sanches S, Braun A, Calsavara V, Barbosa P, Chinen L Clinics (Sao Paulo). 2021; 76:e2971.

PMID: 34644733 PMC: 8478133. DOI: 10.6061/clinics/2021/e2971.


Improved Inception V3 method and its effect on radiologists' performance of tumor classification with automated breast ultrasound system.

Zhang P, Ma Z, Zhang Y, Chen X, Wang G Gland Surg. 2021; 10(7):2232-2245.

PMID: 34422594 PMC: 8340346. DOI: 10.21037/gs-21-328.

References
1.
Rao C, Chianese D, Doyle G, Miller M, Russell T, Sanders Jr R . Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005; 27(1):49-57. View

2.
Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert J . Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003; 162:149-55. DOI: 10.1007/978-3-642-59349-9_13. View

3.
Neurauter A, Bonyhadi M, Lien E, Nokleby L, Ruud E, Camacho S . Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol. 2007; 106:41-73. DOI: 10.1007/10_2007_072. View

4.
Castle J, Morris K, Pritchard S, Kirwan C . Challenges in enumeration of CTCs in breast cancer using techniques independent of cytokeratin expression. PLoS One. 2017; 12(4):e0175647. PMC: 5397021. DOI: 10.1371/journal.pone.0175647. View

5.
Ried K, Eng P, Sali A . Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. Asian Pac J Cancer Prev. 2017; 18(8):2275-2285. PMC: 5697492. DOI: 10.22034/APJCP.2017.18.8.2275. View